This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

IBio Announces Production Of Biosimilar Rituximab With Its IBioLaunchâ¿¢ Technology

NEWARK, Del., Oct. 5, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) , announced that its proprietary iBioLaunch™ technology for the production of biotherapeutic proteins and vaccine antigens in whole green plants has been used to produce a functional monoclonal antibody copy of rituximab, used in the medical treatment of lymphomas, autoimmune diseases, and transplant rejection.  Rituximab is a chimeric mouse-human monoclonal antibody that binds to the CD20 antigen presented on the B-cell surface.

Scientists at iBio's research and development partner, the Fraunhofer USA Center for Molecular Biotechnology, have expressed the antibody heavy and light chains in whole plants using another novel iBioLaunch vector system developed for multi-chain proteins like antibodies.  The expression of rituximab in plants resulted in a balanced expression of heavy and light chains which self-assembled into the appropriate antibody structure, which was then purified from the plant tissue.  

Purified, iBioLaunch-produced rituximab was shown to bind to B lymphocytes from donor blood samples, indicating that it was recognizing its antigen presented on the B-cell surface. In further experiments, plant produced rituximab was incubated at various concentrations with donor peripheral blood mononuclear cells (PBMC), and shown to cause a dose-dependent depletion of B-cells as measured by flow cytometry staining of another B-cell surface antigen, CD19.  At the highest doses tested, greater than 90% of donor B cells were lost from the lymphocyte population, showing that plant-produced rituxmab is able to demonstrate the antigen recognition and target cell cytotoxicity observed with rituximab manufactured in mammalian cell systems.  The B-cell cytotoxicity is specific to rituximab, which was demonstrated in experiments that used another plant-produced monoclonal antibody as a control for any plant-specific B-cell depletion activity.

"The production of functional rituximab in plants suggests that many if not all monoclonal antibodies can be produced using the iBioLaunch™ system," said Terence Ryan, Ph.D., iBio's Senior Vice President. "This success dramatically extends the commercial opportunities for our technology beyond its previous applications for the production of viral antigens for vaccines, and replacement protein biotherapeutics such as alpha-galactosidase, alpha-1 antitrypsin, and C1 esterase inhibitor."

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com.

Forward-Looking Statements

Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

Contacts:

Corporate: Robert Erwin, PresidentiBio, Inc.302-355-2335 rerwin@ibioinc.com

Investor: Douglas Beck, Chief Financial OfficeriBio, Inc.302-355-0923 ir@ibioinc.com

SOURCE iBio, Inc.

Stock quotes in this article: IBIO 
Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs